Journal: Nature medicine

Article Title: Therapeutic cell engineering using surface-conjugated synthetic nanoparticles

doi: 10.1038/nm.2198

Figure Lengend Snippet: Pmel-1 T-cells conjugated with IL-15Sa/IL-21-releasing NPs robustly proliferate in vivo and eradicate established B16 melanomas. Lung and bone marrow tumors were established by tail vein injection of 1×10 6 Gaussia luciferase-expressing B16F10 cells in C57Bl/6 mice. Tumor-bearing animals were treated after 1 week by sublethal irradiation followed by i.v. infusion of 10×10 6 Click beetle red luciferase-expressing Vβ13 + CD8 + Pmel-1 T-cells. One group of mice received Pmel-1 T-cells conjugated with 100 NPs/cell carrying a total dose of 5 μg IL-15Sa/IL-21 (4.03 μg IL-15Sa + 0.93 μg IL-21), control groups received unmodified Pmel-1 T-cells and a single systemic injection of the same doses of IL-15Sa/IL-21 or Pmel-1 T-cells alone. ( a ) Dual longitudinal in vivo bioluminescence imaging of Gaussia luc-expressing B16F10 tumors and CBR-luc-expressing Pmel-1 T-cells. ( b ) Frequencies of Vβ13 + CD8 + Pmel-1 T-cells recovered from pooled lymph nodes of representative animals 16 days after T-cell transfer. ( c ) CBR-luc T-cell signal intensities from sequential bioluminescence imaging every two days after T-cell transfer. Every line represents one animal with each dot showing the whole animal photon count. ( d ) Survival of animals following T-cell therapy illustrated by Kaplan-Meier curves. Shown are six mice/treatment group pooled from three independent experiments.

Article Snippet: The murine melanoma cell line B16F10, the pancreatic islet endothelial cell line MS1, the thymoma cell line EL4 and EG7-OVA, an EL4 cell line stably transfected with the plasmid pAc-neo-OVA which carries a complete copy of chicken ovalbumin (OVA) mRNA, were all purchased from the American Type Culture Collection (ATCC).

Techniques: In Vivo, Injection, Luciferase, Expressing, Irradiation, Control, Imaging

Journal: Cell

Article Title: Macrophage-mediated myelin recycling fuels brain cancer malignancy

doi: 10.1016/j.cell.2024.07.030

Figure Lengend Snippet:

Article Snippet: DF1-shNF1, DF1 chicken fibroblasts (ATCC) with a short hairpin against murine NF1 , Dr Tatsuya Ozawa and Dr Eric Holland , N/A.

Techniques: Blocking Assay, Recombinant, Staining, Flow Cytometry, Cholesterol Assay, cDNA Synthesis, Plasmid Preparation, Expressing, Software, Imaging, Microscopy, Real-time Polymerase Chain Reaction

Journal: Nature Communications

Article Title: Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy

doi: 10.1038/s41467-021-21497-6

Figure Lengend Snippet: a IVIS imaging depicting the accumulation of imNA αPD1 & αPDL1 in 4T1 tumors. b Quantification of mAb accumulation in tumor tissues. Data are presented as means ± s.d. n = 3 biologically independent mice. Statistical significance was calculated via two-way ANOVA followed by the Tukey post-hoc test. * P < 0.05; ** P < 0.01. c Engagement of 4T1-GFP tumor cells and CD8 + T cells in tumor tissues. Scale bars, 200 mm. d Experimental protocol for the B16-F10 melanoma model used in e – g , the equivalent injection dose of αPD1 and αPDL1 was 2.5 mg/kg. Individual ( e ), and average ( f ) tumor growth curves of B16-F10 tumors in different groups. Data are presented as means ± s.d. n = 10 biologically independent mice. g The abundance of CD8 + T cells in tumor tissues at the end of treatment. Data are presented as means ± s.d. n = 6-7 biologically independent mice (IgG control: n = 7; other groups: n = 6). Flow cytometry to evaluate the percentages of granzyme-secreting ( h ), IFN-γ-secreting ( i ), and IL-2-secreting CTLs ( j ) in melanoma tumors. Data are presented as means ± s.d. n = 5–7 biologically independent mice. For h , imNA αPD1 & αPDL1 : n = 5, other groups: n = 6; for i , IgG control: n = 7, Free αPD1 & αPDL1 : n = 6, other groups, n = 5; for j , IgG control: n = 7, other groups, n = 6. k Experimental protocol for the 4T1 breast cancer model used in l – m . l Individual tumor growth curves. m Tumor growth rates are shown in ( l ) at 24 days post-inoculation. Data are presented as means ± s.d. n = 10–12 biologically independent mice (IgG control: n = 12; other groups: n = 10). n Experimental protocol for the lung metastatic breast cancer model used in o – q . o In vivo bioluminescence imaging (BLI) of pulmonary metastases in mice at 16 days post-injection. p Ex vivo BLI of pulmonary metastases. q Tumor nodules on the lung tissues. Data are presented as mean ± s.d. n = 5 biologically independent mice. Statistical significance was calculated via one-way ANOVA with the Tukey post-hoc test. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. Source data are provided as a Source Data file.

Article Snippet: The B16-F10 murine melanoma cells and 4T1 murine mammary carcinoma cells were obtained from the American Type Culture Collection (ATCC).

Techniques: Imaging, Injection, Control, Flow Cytometry, In Vivo, Ex Vivo